Childhood cancers trials in Denmark

In Denmark 99 Also abroad 2459

99 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Copenhagen Oe
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Copenhagen, Odense C
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Where
Aarhus N, Copenhagen Oe, Odense C
Age
15 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
Phase 2Taking people
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
Where
Copenhagen Oe
Age
12 years to 17 years
People
15 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07700758 · EU 2025-524515-37-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Copenhagen Oe
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 2Taking people
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Where
Copenhagen Oe
Age
18 months to 64 years
People
24 worldwide
Run by
Jakob Stenman
See details and how to joinNCT04903899 · EU 2023-503684-42-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Aarhus N, Copenhagen Oe, Odense C
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 1/2Taking people
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
København Ø
Age
6 months to 30 years
People
65 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05533775
Phase 1/2Taking people
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Where
Copenhagen Oe
Age
Up to 17 years
People
37 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00
Phase 3Taking people
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
Where
Aarhus N, Copenhagen Oe, Gistrup, Odense C
Age
6 years to 27 years
People
50
Run by
Odense University Hospital
See details and how to joinNCT06905587 · EU 2023-507926-18-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Aarhus N, Copenhagen Oe, Odense C, Roskilde
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Copenhagen Oe
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1/2Taking people
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Where
Copenhagen Oe
Age
1 month to 17 years
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00
Phase 1Taking people
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
Where
Copenhagen Oe
Age
12 years and over
People
464 worldwide
Run by
Debiopharm International SA
See details and how to joinNCT04855656 · EU 2023-510063-35-00
No phaseTaking people
Pharmacokinetics of Dexamethasone in Childhood ALL and Reduction in Bone Mineral Density
Where
Aalborg, Aarhus N, Copenhagen, Odense
Age
1 year to 17 years
People
100
Run by
University of Aarhus
See details and how to joinNCT06367725
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Aarhus N, Copenhagen Oe, Odense C
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 3Taking people
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
Where
Aarhus, Copenhagen, Herlev
Age
4 years and over
People
530 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07871864
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Copenhagen Oe
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Where
Aalborg, Aarhus N, Copenhagen Oe, Odense C
Age
Up to 17 years
People
137 worldwide
Run by
GPOH gGmbH
See details and how to join2022-501454-11-00 · EU 2022-501454-11-00
Phase 3Taking people
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Where
Aarhus N, Copenhagen Oe, Odense C
Age
6 months and over
People
433 worldwide
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT05476939 · EU 2023-506027-29-00
No phaseTaking people
Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)
Where
Herlev
People
60
Run by
Copenhagen University Hospital at Herlev
See details and how to joinNCT06802991
Phase 3Not yet taking people in Denmark
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Where
Aarhus N, Copenhagen Oe, Odense C
Age
Up to 5 years
People
96 worldwide
Run by
Nationwide Children's Hospital
See details and how to joinNCT07291102 · EU 2024-517133-40-00
Phase 2/3Taking people
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Where
Copenhagen
Age
3 months to 25 years
People
1,000 worldwide
Run by
Bambino Gesù Hospital and Research Institute
See details and how to joinNCT07297914 · EU 2025-522052-13-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Aarhus N, Copenhagen Oe, Odense C
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00